Sandbox:tavr: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 103: Line 103:
* [[LVEF]] ≥ 50%
* [[LVEF]] ≥ 50%
|}
|}
=== Risk Assessment ===
Underlying risk for SAVR is basic component to consider patient for TAVR. This risk assessment is based on several components that include:
* The Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) score. '''To calculate this score please click''' [http://riskcalc.sts.org/stswebriskcalc/#/calculate here].
* Frailty
* Main organ system dysfunction
* Procedure-specific impediments

Revision as of 19:58, 9 January 2017

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Seyedmahdi Pahlavani, M.D. [2]

Transcatheter Aortic Valve Replacement (TAVR) Procedure Guide Microchapters
Overview
Causes
FIRE
Diagnosis
Treatment
General Approach
Choice of Intervention
Type of Valve and Discharge Anticoagulation Therapy
Do's
Don'ts

Overview

During the past 50 years, surgical aortic valve replacement (SAVR) was the standard of care for patients with severe AS. Global aging has raised concerns about safety and possibility of surgical procedure in old patients with associated co-morbidities. Transcatheter aortic valve replacement (TAVR) created a new era of safety for this population and enabled physicians to replace the stenotic valve with more certainty.
Preoperation evaluation, selecting the appropriate imaging modality, issues in TAVR procedure and patient follow up are the areas of more focused importance.
We will describe these factors based on the recent expert consensus for TAVR procedure.

Definition

The most important step is to define the severity of AS and appropriate patient that need TAVR. Severe sypmtomatic (Stage D) AS is considered as TAVR candidate.

Severe symptomatic AS (stage D)
STAGE DEFINITION SYMPTOMS VALVE ANATOMY VALVE HEMODYNAMICS HEMODYNAMIC CONSEQUENCES
D1 Symptomatic severe high-gradient AS
  • Exertional dyspnea or decreased exercise tolerance
  • Exertional angina
  • Exertional syncope or presyncope
Severe calcification or congenital stenosis with severely reduced opening
  • Vmax ≥ 4 m/s or mean ΔP ≥ 40 mmHg
  • AVA ≤ 1.0 cm² but may be larger with mixed AS and AR
D2 Symptomatic severe low-flow/low gradient AS with reduced LVEF Severe calcification or congenital stenosis with severely reduced leaflet motion
  • AVA ≤ 1.0 cm² with resting aortic Vmax < 4 m/s or mean ΔP ≥ 40 mmHg
  • Dobutamine stress echo shows AVA ≤ 1.0 cm² with Vmax ≥ 4 m/s at any flow rate
  • LV diastolic dysfunction
D3 Symptomatic severe low gradient with normal LVEF Severe calcification with severely reduced leaflet motion
  • AVA ≤ 1.0 cm² with Vmax < 4 m/s or mean ΔP ≤ 40 mmHg
  • AVA ≤ 0.6 cm²
  • Stroke volume index < 35 mL/m²
  • Increased LV relative wall thickness
  • Small LV chamber with low stroke volume
  • Restrictive diastolic filling

Risk Assessment

Underlying risk for SAVR is basic component to consider patient for TAVR. This risk assessment is based on several components that include:

  • The Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) score. To calculate this score please click here.
  • Frailty
  • Main organ system dysfunction
  • Procedure-specific impediments